Adverse drug reactions in the paediatric population in denmark: A retrospective analysis of reports made to the danish medicines agency from 1998 to 2007

Drug Safety

Volumn 33, Issue 4, 2010, Pages 327-339

  Aagaard, Lise ^a,b   Weber, Camilla Blicher ^a   Hansen, Ebba Holme ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FKL Research Centre for Quality in Medicine Use   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; BOSENTAN; BUDESONIDE; CITALOPRAM; DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS NORGESTIMATE; FELBAMATE; FLUOXETINE; GEFITINIB; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HUMAN GROWTH HORMONE; IBUPROFEN; INSULIN GLARGINE; IRON; ISOTRETINOIN; LAMOTRIGINE; MEASLES MUMPS RUBELLA VACCINE; MESALAZINE; METHOHEXITAL; METHOTREXATE; METHYLPREDNISOLONE; PIVAMPICILLIN; SOMATOMEDIN C; UNINDEXED DRUG; VACCINE; VALPROIC ACID;

ABDOMINAL PAIN; ACUTE LEUKEMIA; ARTICLE; AUTISM; BRADYCARDIA; BRONCHOSPASM; CEREBROVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHORIOAMNIONITIS; DENMARK; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG ERUPTION; DRUG FEVER; DRUG SURVEILLANCE PROGRAM; ERYTHEMA MULTIFORME; ESOPHAGUS ULCER HEMORRHAGE; FATIGUE; FEBRILE CONVULSION; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; GUILLAIN BARRE SYNDROME; HEALTH CARE PERSONNEL; HEART ARREST; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEPATITIS; HUMAN; HYDROCEPHALUS; HYPERHIDROSIS; INJECTION SITE REACTION; LIVER FUNCTION; LUNG EMBOLISM; NECROTIZING COLITIS; NEWBORN SEPSIS; OCCLUSIVE CEREBROVASCULAR DISEASE; PEDIATRICS; PERSISTENT PULMONARY HYPERTENSION; PRIORITY JOURNAL; PURPURA; RESTLESSNESS; SEX DIFFERENCE; SHOCK; SIDE EFFECT; STILLBIRTH; SUDDEN DEATH; SUDDEN INFANT DEATH SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; URTICARIA; VOMITING;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DENMARK; DRUG TOXICITY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; PHYSICIAN'S PRACTICE PATTERNS; SEX FACTORS;

EID: 77949639990     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11319100-000000000-00000     Document Type: Article

References (30)

1. Le J, Nguyen T, Law AV, et al. Adverse drug reactions among children over a 10-year period. Pediatrics 2006; 118: 555-562
2. Temple ME, Robinson RF, Miller JC, et al. Frequency and preventability of adverse drug reactions in paediatric patients. Drug Saf 2004; 27: 819-829
3. FDA Modernization Act of 1997 [online]. Available from URL: http://www.fda.gov/MedicalDevices/DeviceRegulation andGuidance/Overview/ MedicalDeviceProvisionsofFDA ModernizationAct/ucm136671.htm [Accessed 2009 Oct 7].
4. RegulationECNo. 1901/2006 of the European Parliament and the Council of 12 December 2006 on Medicinal Products for Paediatric Use and Amending Regulation [online]. Available from URL http://ec.europa.eu/enterprise/ pharmaceuticals/ eudralex/vol-1/reg-2006-1901/reg-2006-1901-en.pdf [Assessed 2009 Oct 7].
5. Hansen EH. Technology assessment in a user perspective: experiences with drug technology. Int J Technol Assess Health Care 1992; 8: 150-165
6. Aagaard L, Soendergaad B, Stenver DI, et al. Knowledge creation about ADRs: turning the perspective from the rearview mirror to the projector? Br J Clin Pharmacol 2008; 65: 364-376
7. Keinonen T, Miettinen P, Saano V, et al. Clinical trials in children and healthy volunteers: quality and characteristics of notifications reviewed by the regulatory agencies in Finland. Paed Perinat Drug Ther 2003; 5: 175-182
8. Sammons HM, Choorara I. Clinical trials of medication in children, 1996-2002. Eur J Clin Pharmacol 2005; 61: 165-167
9. Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77-83
10. Meyboom RH. Adverse reactions to drugs in children, experiences with "spontaneous monitoring" in the Netherlands. Bratisl Lek Listy 1991; 92: 554-559
11. Morales-Olivas FJ, Martinez-Mir I, Ferrer JM, et al. Adverse drug reactions in children reported by means of the yellow card in Spain. J Clin Epidemiol 2000; 53: 1076-1080
12. Moore TJ, Weiss SR, Kaplan S, et al. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002; 110: e53
13. Kimland E, Rane A, Ufer M, et al. Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharm Drug Saf 2005; 14: 493-499
14. Carleton BC, Smith MA, Gelin MN, et al. Paediatric ad-verse drug reaction reporting: understanding and future directions. Can J Clin Pharmacol 2007; 14: e45-57
15. Ackers R, Murray ML, Besag FMC, et al. Prioritizing chil-dren's medicines for research: a pharmacoepidemiological study of antiepileptic drugs. Br J Clin Pharmacol 2006; 63: 689-697
16. van de Vrie-Hoekstra NW, de Vries TW, van den Berg PB, et al. Antiepileptic drug utilization in children from 1997-2005: a study from the Netherlands. Eur J Clin Pharmacol 2008; 64: 1013-1020
17. Aagaard L, Soendergaard B, Andersen E, et al. Creating knowledge about adverse drug reactions: a critical analysis of the Danish reporting system from 1968 to 2005. Soc Sci Med 2007; 65: 1296-1309
18. Roden S. Good case management and reporting practices. In: Mann RD, Andrews EB, editors. CIOMS working groups and their contribution to pharmacovigilance. Chapter V. Middlesex: John Wiley & Sons, Ltd, 2007
19. Aagaard L, Stenver DI, Hansen EH. Structures and processes in spontaneous reporting systems: a comparative study of Australia and Denmark. Pharm World Sci 2008; 30: 563-570
20. Medical Dictionary for Regulatory Activities [online]. Avail-able from URL: http://www.meddramsso.com [Accessed 2008 Aug 20].
21. Fraunhofer Institute for Systems and Innovation Research. Assessment of the European community system of pharma-covigilance 2004 [online]. Available from URL: http://www.isi. fraunhofer.De/t/projekte/medpharm-e-rt-eurovigilance. htm [Accessed 2009 Dec 31].
22. Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf 2009; 32: 1067-1074
23. Aagaard L, Thirstrup S, Hansen EH. Opening the white boxes: the licensing documentation of efficacy and safety of psychotropic medicines for children. Pharm Drug Saf 2009; 18: 401-411
24. Cheung A, Sacks D, Dewa CS, et al. Paediatric prescribing practices and the FDA black-box warning on anti-depressants. J Dev Behav Pediatr 2008; 29: 213-215
25. European Medicines Agency finalises review of antidepres-sants in children and adolescents (ref. EMEA/CHMP/ 128918/ 2005 corr. London, 25 April 2005 [online]. Available from URL: www.emea.europa.eu/pdfs/human/press/pr/1289 1805en.pdf [Accessed 2010 Jan 29].
26. Press release: meeting highlights from the Committee for Medi-cinal Products for Human Use (ref. EMEA/431407/2007). London, 19 July 2007 [online]. Available from URL: www. emea.europa.eu/pdfs/human/press/pr/43140707en.pdf [Accessed 2010 Jan 29].
27. Sanghera N, Chan PY, Khaki ZF, et al. Interventions of hospital pharmacists in improving drug therapy in children: a systematic literature review. Drug Saf 2006; 29: 1031-1047
28. Sturkenboom CJM, Verhamme KMC, Nicolosi A, et al. Drug use in children: cohort study in three European countries. BMJ 2008; 24: 337: a2245
29. de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf 2008; 31: 515-524
30. Schirm E, Tobi H, van Puijenbroek EP, et al. Reported adverse drug reactions and their determinants in Dutch children outside the hospital. Pharm Drug Saf 2004; 13: 159-165